Suppr超能文献

含萘醌和喹喔啉二酮骨架的混合分子作为抗肿瘤药物。

Hybrid Molecules Containing Naphthoquinone and Quinolinedione Scaffolds as Antineoplastic Agents.

机构信息

Laboratory of Bioorganic Chemistry, Department of Physics, University of Trento, 38123 Trento, Italy.

Laboratory of Translational Genomics, Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, 38123 Trento, Italy.

出版信息

Molecules. 2022 Aug 3;27(15):4948. doi: 10.3390/molecules27154948.

Abstract

In recent decades, molecular hybridization has proven to be an efficient tool for obtaining new synthetic molecules to treat different diseases. Based on the core idea of covalently combining at least two pharmacophore fragments present in different drugs and/or bioactive molecules, the new hybrids have shown advantages when compared with the compounds of origin. Hybridization could be successfully applied to anticancer drug discovery, where efforts are underway to develop novel therapeutics which are safer and more effective than those currently in use. Molecules presenting naphthoquinone moieties are involved in redox processes and in other molecular mechanisms affecting cancer cells. Naphthoquinones have been shown to inhibit cancer cell growth and are considered privileged structures and useful templates in the design of hybrids. The present work aims at summarizing the current knowledge on antitumor hybrids built using 1,4- and 1,2-naphthoquinone (present in natural compounds as lawsone, napabucasin, plumbagin, lapachol, α-lapachone, and β -lapachone), and the related quinolone- and isoquinolinedione scaffolds reported in the literature up to 2021. In detail, the design and synthetic approaches adopted to produce the reported compounds are highlighted, the structural fragments considered in hybridization and their biological activities are described, and the structure-activity relationships and the computational analyses applied are underlined.

摘要

在最近几十年中,分子杂交已被证明是获得用于治疗不同疾病的新合成分子的有效工具。基于至少将两种药效团片段共价结合到不同药物和/或生物活性分子中的核心思想,与原始化合物相比,新的杂种显示出优势。杂交已成功应用于抗癌药物发现,目前正在努力开发比目前使用的药物更安全、更有效的新型疗法。具有萘醌部分的分子参与氧化还原过程和影响癌细胞的其他分子机制。已经表明萘醌能抑制癌细胞生长,并且被认为是特权结构,并且在设计杂种时是有用的模板。本工作旨在总结截至 2021 年,使用 1,4-和 1,2-萘醌(存在于天然化合物如 lawsone、napabucasin、plumbagin、lapachol、α-lapachone 和β -lapachone 中)和文献中报道的相关喹诺酮和异喹啉二酮支架构建的抗肿瘤杂种的现有知识。详细地,突出显示了用于生产报道的化合物的设计和合成方法,描述了杂交中考虑的结构片段及其生物活性,并强调了结构-活性关系和应用的计算分析。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/543e/9370406/adfec5526178/molecules-27-04948-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验